Avadel Pharma to Present at June 2024 Investor Conferences

Avadel Pharmaceuticals plc, a company listed on Nasdaq under the ticker symbol AVDL, has revealed its participation in two significant upcoming investor conferences. The biopharmaceutical company, which is dedicated to improving medicine through innovative approaches, has announced that its management team will take part in fireside chats at these conferences.

The company will first participate in the Jefferies Global Healthcare Conference, where the fireside chat is scheduled for Thursday, June 6, at 10:30 a.m. Eastern Time. The second engagement is at the Goldman Sachs 45th Annual Global Healthcare Conference, with their fireside chat set for Wednesday, June 12, at 3:20 p.m. Eastern Time. Both events aim to provide valuable insights and updates on Avadel's strategic initiatives and developments.

For those unable to attend in person, Avadel Pharmaceuticals has arranged for a live webcast of these sessions. The webcasts, along with archived recordings, will be accessible on the company’s Investor Relations website, investors.avadel.com, for a duration of 90 days after each conference. This measure ensures that stakeholders and interested parties can stay informed about the company's progress and engage with its vision and strategies.

Avadel Pharmaceuticals plc's mission is centered on transforming lives by transforming medicines. The company employs innovative solutions to develop medications that address the gaps and challenges patients encounter with existing treatments. Their flagship commercial product, LUMRYZ™, has gained approval from the U.S. Food & Drug Administration (FDA). LUMRYZ™ stands out as the first and only once-at-bedtime oxybate designed to treat cataplexy or excessive daytime sleepiness (EDS) in adults suffering from narcolepsy. This FDA approval underscores Avadel's commitment to enhancing the quality of life for patients through groundbreaking medical solutions.

Avadel's core philosophy revolves around patient-centric innovation, and its efforts are directed towards creating treatment options that significantly improve patient outcomes. The company’s participation in these high-profile healthcare conferences is an opportunity to highlight its progress and future plans to a broad audience, including investors, analysts, and industry experts.

The management team, through their participation in the fireside chats, will provide deeper insights into the company’s strategy, product pipeline, and market opportunities. These dialogues are expected to shed light on Avadel’s ongoing and future initiatives, demonstrating its dedication to advancing healthcare solutions.

In summary, Avadel Pharmaceuticals plc is poised to engage with the investment community at the upcoming Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. The sessions will be available via live webcast and archived for future access, ensuring that all interested parties have the opportunity to engage with and understand the company's trajectory. Avadel continues to lead with its innovative approach to medicine, aiming to make a significant impact on the lives of patients through its approved and developing products.